ConjuChem Science and Technology

The unique Drug Affinity Complex (DAC™) and Preformed Conjugate-Drug Affinity Complex (PC-DAC™) technology platforms, created by ConjuChem, are broadly applicable to most traditional small compounds. When applied to therapeutic peptides, these technologies have shown the ability to create patentable new drugs by protecting the peptides from peptidase degradation and renal excretion. By extending their otherwise inadequate duration of activity in the body, the DAC™ and PC-DAC™ technology platforms can convert peptides into attractive commercial drug candidates.